Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Rheumatology

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/RHEUMATOLOGY/41.4.430PMID 11961174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.

  2001cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.

  2000cited by this paper
• Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)

  2000cited by this paper
• Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Tumor necrosis factor inhibitors for rheumatoid arthritis.

  1999cited by this paper
• Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• EFFICACY AND TOLERABILITY OF WEEKLY SUBCUTANEOUS INJECTIONS OF THE FULLY HUMAN ANTI-TNF-ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS-RESULTS OF A PHASE I STUDY

  1998cited by this paper
• Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity.

  1998cited by this paper
• Combination therapy in rheumatoid arthritis: updated systematic review.

  1998cited by this paper
• Combination therapy with biologic agents in rheumatoid arthritis: perils and promise.

  1998cited by this paper
• Combination of second-line antirheumatic drugs.

  1997cited by this paper
• The use of folates concomitantly with low-dose pulse methotrexate.

  1997cited by this paper
• Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years.

  1997cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.

  1997cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Adverse events in methotrexate-treated rheumatoid arthritis patients.

  1995cited by this paper
• TNFα Is an Effective Therapeutic Target for Rheumatoid Arthritis a

  1995cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial

  1994cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

  1994cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

  1994cited by this paper
• Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.

  1993cited by this paper
• Methotrexate--the relationship between dose and clinical effect.

  1993cited by this paper
• The relative toxicity of alternative therapies for rheumatoid arthritis: implications for the therapeutic progression.

  1993cited by this paper
• Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1992cited by this paper
• Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1992cited by this paper
• Long-term second-line treatment: a prospective drug survival study.

  1992cited by this paper
• Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.

  1992cited by this paper
• Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial.

  1991cited by this paper
• Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

  1990cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis.

  1989cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• A double‐blind, placebo‐controlled trial

  1986cited by this paper

• Altered Tumor Necrosis Factor Response in Neurologic Postacute SARS-CoV-2 Syndrome

  2023cites this paper
• Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management

  2023cites this paper
• Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study

  2022cites this paper
• Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics

  2020cites this paper
• Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

  2020cites this paper
• Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor.

  2020cites this paper
• A Review on Comparison of Effectiveness and Safety of Disease Modifying Anti-Rheumatoid Drugs Used in Patients with Rheumatoid Arthritis

  2020cites this paper
• Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis

  2020cites this paper
• Physiologie de la douleur : aspects psychophysiologiques et mécanismes périphériques

  2019cites this paper
• Factors Predicting Early Discontinuation of Methotrexate as a First-Line Treatment for Rheumatoid Arthritis in Italy: Results from the GISEA Registry

  2019cites this paper
• Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis

  2019cites this paper
• Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis

  2018cites this paper
• Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data

  2018cites this paper
• Physiologie de la douleur : aspects psychophysiologiques et mécanismes périphériques

  2018cites this paper
• Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis

  2018cites this paper
• Discovery of Potent Small-Molecule Inhibitors of Ubiquitin-Conjugating Enzyme UbcH5c from α-Santonin Derivatives.

  2017cites this paper
• OP-BRHE160370 1247..1250

  2017cites this paper
• Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery

  2016cites this paper
• Stratified medicine in rheumatoid arthritis—the MATURA programme

  2016cites this paper
• University of Birmingham Rheumatoid Arthritis patient perceptions on the value of predictive testing for treatments:

  2016cites this paper
• Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study

  2016cites this paper
• A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis

  2016cites this paper
• SAT0009 Investigation of Differential Methylation as A Potential Biomarker of Methotrexate Response in Patients with Rheumatoid Arthritis

  2016influential citation
• Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis.

  2015cites this paper
• Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project.

  2015cites this paper
• Current and future trends in biomarker discovery and development of companion diagnostics for arthritis

  2015cites this paper
• Genetic and epigenetic predictors of responsiveness to treatment in RA

  2014cites this paper
• Treatment of Chronic, Noninfectious, Nonnecrotizing Scleritis with Tumor Necrosis Factor Alpha Inhibitors

  2014cites this paper
• Genetics and the impact on treatment protocols in patients with rheumatoid arthritis

  2012cites this paper
• Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure.

  2012cites this paper
• Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study

  2012cites this paper
• Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis

  2012cites this paper
• Bridging the gap between aggregate data and individual patient management: A Bayesian approach

  2011cites this paper
• Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.

  2011cites this paper
• [Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"].

  2011cites this paper
• Effect of the Application of Trial Inclusion Criteria on the Efficacy of Adalimumab Therapy in a Rheumatoid Arthritis Cohort

  2011cites this paper
• Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based study.

  2010cites this paper
• Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis

  2009cites this paper
• Cross-validation of a clinical pharmacogenetic model to predict the efficacy of MTX monotherapy in established RA

  2009cites this paper
• Evaluation of new drugs in daily clinical practice : anti-TNF alpha in rheumatoid arthritis patients

  2008cites this paper
• Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

  2008cites this paper
• v) Biological therapy in the management of inflammatory arthritis with particular reference to orthopaedic surgery

  2007cites this paper
• Non-redundant and critical roles for leukotriene B4 receptors BLT1 and BLT2 in mouse models of inflammatory arthritis.

  2007cites this paper
• The role of TNF- a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

  2007cites this paper
• The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.

  2007cites this paper
• The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

  2007cites this paper
• The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice

  2007cites this paper
• [Therapeutic maintenance level of methotrexate in rheumatoid arthritis].

  2006cites this paper
• Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis

  2005cites this paper
• Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy.

  2005cites this paper
• Adalimumab for treating rheumatoid arthritis.

  2005cites this paper
• Adalimumab for treating rheumatoid arthritis.

  2005cites this paper
• Hyperalgesia and allodynia: peripheral mechanisms.

  2005cites this paper
• Hyperalgésie et allodynie : les mécanismes périphériques

  2005cites this paper
• Hyperalgésie et allodynie : les mécanismes périphériques Hyperalgesia and allodynia: Peripheral mechanisms e

  2005cites this paper
• Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis.

  2004cites this paper
• Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

  2004cites this paper
• Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

  2004cites this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cites this paper
• Adalimumab: a review of its use in rheumatoid arthritis.

  2004cites this paper
• The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.

  2004cites this paper
• Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients

  2004cites this paper
• The use of TNF-α blocking agents in rheumatoid arthritis: an overview

  2004cites this paper
• Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate

  2004cites this paper
• Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

  2003cites this paper
• Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

  2003cites this paper
• Adalimumab – a new TNF-α antibody for treatment of inflammatory joint disease

  2003cites this paper
• Disease‐modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment

  2003cites this paper
• Studies of pharmacological interventions and pathogenesis of rheumatoid arthritis

  2002cites this paper
• Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

  2002cites this paper
• Bmc Musculoskeletal Disorders Tumor Necrosis Factor Alpha Drugs in Rheumatoid Arthritis: Systematic Review and Metaanalysis of Efficacy and Safety

  year unknowncites this paper